NEISSERIA MENINGITIDIS OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197

Summary

Neisseria Meningitidis Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm197 (CHEMBL6068368) is an approved vaccine component; indicated across 2 conditions including meningococcal meningitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 2 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068368
Name	NEISSERIA MENINGITIDIS OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197
Type	Vaccine component
Max phase	4

Also known as: Menveo

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
meningococcal meningitis	4	MONDO:0018059	EFO:1001040

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	3
PHASE2/PHASE3	2
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07204457	PHASE2/PHASE3	RECRUITING	Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
NCT00901940	PHASE3	COMPLETED	Understanding the Immune Response to Meningitis Vaccines
NCT01192997	PHASE2/PHASE3	COMPLETED	Comparison of Two Meningococcal ACWY Conjugate Vaccines
NCT07183371	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M
NCT07320716	PHASE2	NOT_YET_RECRUITING	Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children
NCT02676895	PHASE2	COMPLETED	A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults
NCT05739292	PHASE1	COMPLETED	Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).